Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
UK-based digital therapy company focused on mental disorders.
Big Health is a digital therapeutics company dedicated to helping millions back to good mental health. Its first digital therapeutics Sleepio, for poor sleep and Daylight, for worry and anxiety are fully automated, scalable cognitive and behavioural programs. Big Health’s products are backed by 50 published clinical papers including 13 randomised controlled trials (RCTs), and are cited in leading clinical guidelines including the American College of Physicians and NICE. Today, over 12 million people worldwide have reimbursed access to Big Health’s products, via leading employers in the US and the UK’s NHS.
More Big Health news
Gilde Healthcare company Big Health expands into adolescent mental health through acquisition of Limbix
Gilde Healthcare company Big Health builds out its Leadership Team with the appointment of five key Executives
Gilde Healthcare company Big Health receives NICE digital therapeutics guidance confirming clinical and cost effectiveness
Gilde Healthcare Portfolio Company Big Health Adds Former FDA Deputy Commissioner Anand Shah to Its Board of Directors
Gilde Healthcare Portfolio Company Big Health Raises $75 Million in Series C Funding
Gilde Healthcare leads $39 million in Series B financing in Big Health
Venture&Growth
SpliceBio
SpliceBio is a Spanish therapeutics company addressing the key limitations of current gene therapy. It harnesses its proprietary Protein Splicing platform to develop next-generation gene therapies, based on engineered inteins pioneered at the Muir Lab at Princeton University. The company
Venture&Growth
Fire1
Irish MedTech company focused on remote monitoring of heart failure patients.
Venture&Growth
Okami Medical
Okami Medical, based in Aliso Viejo, California and founded in 2017 by the Inari team through the Inceptus Medical incubator, is a commercial-stage company focused on innovative solutions for peripheral vascular embolization across a wide range of conditions. The company’s